ESPR - Esperion Therapeutics Inc Stock Price, Fair Value and News

$2.23+0.04 (+1.83%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

ESPR Price Action

Last 7 days

-2.7%

Last 30 days

-9.1%

Last 90 days

30.4%

Trailing 12 Months

-6.0%

ESPR RSI Chart

ESPR Valuation

Market Cap

439.4M

Price/Earnings (Trailing)

-5.06

Price/Sales (Trailing)

1.49

Price/Free Cashflow

-16.85

ESPR Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

ESPR Fundamentals

ESPR Revenue

Revenue (TTM)

295.5M

Rev. Growth (Yr)

52%

Rev. Growth (Qtr)

-30.07%

ESPR Earnings

Earnings (TTM)

-86.8M

Earnings Growth (Yr)

28.43%

Earnings Growth (Qtr)

52.32%

ESPR Profitability

Return on Equity

23.44%

Return on Assets

-27.62%

Free Cashflow Yield

-5.93%

ESPR Investor Care

Shares Dilution (1Y)

73.27%

Diluted EPS (TTM)

-0.59

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	229.7M	277.8M	295.5M	0
2023	81.0M	87.9M	102.9M	116.3M
2022	89.3M	67.5M	72.1M	75.5M
2021	233.7M	62.1M	72.7M	78.4M
2020	168.2M	188.0M	207.8M	227.5M
2019	0	0	0	148.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Esperion Therapeutics Inc

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

CEO	Mr. Sheldon L. Koenig
WEBSITE	esperion.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	199

Esperion Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Esperion Therapeutics Inc? What does ESPR stand for in stocks?

ESPR is the stock ticker symbol of Esperion Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Esperion Therapeutics Inc (ESPR)?

As of Fri Dec 20 2024, market cap of Esperion Therapeutics Inc is 431.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ESPR stock?

You can check ESPR's fair value in chart for subscribers.

Is Esperion Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ESPR is over valued or under valued. Whether Esperion Therapeutics Inc is cheap or expensive depends on the assumptions which impact Esperion Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ESPR.

What is Esperion Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, ESPR's PE ratio (Price to Earnings) is -4.97 and Price to Sales (PS) ratio is 1.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ESPR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Esperion Therapeutics Inc's stock?

In the past 10 years, Esperion Therapeutics Inc has provided -0.244 (multiply by 100 for percentage) rate of return.